The conversation discusses experiences with Procapil for hair loss treatment. A user inquires about purchasing Procapil and provides a link to a product website.
Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.
Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The user started with topical minoxidil, then used finasteride, and saw the most improvement with oral minoxidil despite experiencing significant shedding. They plan to get a hair transplant for their temples.
Clascoterone, a topical anti-androgen, shows promise for treating female pattern hair loss without systemic side effects, offering a potential alternative to minoxidil. It could also benefit men who experience side effects from finasteride.
Temporal peaks are crucial for a natural-looking hair transplant, but they are challenging to achieve due to the need for precise angles and appropriate hair thickness. Many users emphasize the importance of finding a skilled surgeon and using finasteride to maintain hairline stability.
Fluridil was discussed as a hair loss treatment, with some users experiencing side effects like lethargy and chest tightness. Users also mentioned other treatments like RU58841 and finasteride, with mixed opinions on their effectiveness.
The conversation discusses experimenting with microneedling for hair loss, with OP considering using a 3mm derma-stamp. Other users advise against going beyond 1.5mm to avoid damage.
Liquid minoxidil causes scalp flaking due to propylene glycol, leading some to consider switching to foam or PG-free liquid with applicators. Foam is often recommended for ease and effectiveness, while PG-free liquid is less common but can reduce irritation.
The conversation is about a user switching from finasteride to dutasteride after 4 years due to continued hair recession and miniaturization. The user plans to gradually increase to 1mg of dutasteride daily.
The user has been taking 3.75mg of finasteride weekly for 8 months, which has improved their hairline and hair texture. They shared a humorous encounter with a bald mechanic who complimented their hair, unaware of the finasteride use.
The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.
The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.
The conversation discusses the anticipation of clascoterone scalp treatment results for hair loss, with concerns about its availability and high cost. Users express hope for positive outcomes and affordable access.
The conversation expresses skepticism about the effectiveness of new hair loss treatments, comparing them to 2% minoxidil and criticizing the lack of substantial data. Users doubt the claims of a non-hormonal treatment and mention previous disappointments with products like JXL-069.
PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.
miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.
A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.
The user is experiencing severe hair shedding despite using minoxidil, finasteride, ketoconazole shampoo, and dermarolling. They are considering changing treatments after stopping dermarolling and switching finasteride brands worsened the shedding.
The user is using minoxidil and finasteride to treat hair loss and is concerned about shedding and potential aggressive hair loss. They noticed some regrowth in trichoscopy pictures but are unsure about real-life changes.
Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The user is experiencing hair shedding despite using finasteride, minoxidil, and microneedling, and is concerned about the non-linear progress. Other users share similar experiences, suggesting shedding is normal and cyclical, with some recommending less frequent microneedling.
A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.
Minoxidil can cause scalp dryness and flaking, leading to hair shedding when exfoliating. Alternatives like oral Minoxidil, finasteride, and ketoconazole shampoo are suggested to manage these issues.